메뉴 건너뛰기




Volumn 57, Issue 10, 2016, Pages 2245-2258

The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies

Author keywords

Gram negative bacteria; Hematologic malignancies; Multidrug resistant

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; BETA LACTAMASE AMPC; CEFTOLOZANE PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

EID: 84982850744     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2016.1193859     Document Type: Review
Times cited : (43)

References (111)
  • 1
    • 84876334028 scopus 로고    scopus 로고
    • Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients
    • C.Gudiol, M.Bodro, A.Simonetti,. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013;19:474–479.
    • (2013) Clin Microbiol Infect , vol.19 , pp. 474-479
    • Gudiol, C.1    Bodro, M.2    Simonetti, A.3
  • 2
    • 84859962764 scopus 로고    scopus 로고
    • Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies
    • P.Cornejo-Juárez, C.Pérez-Jiménez, J.Silva-Sánchez,. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies. PLoS One. 2012;7:e35780.
    • (2012) PLoS One , vol.7 , pp. e35780
    • Cornejo-Juárez, P.1    Pérez-Jiménez, C.2    Silva-Sánchez, J.3
  • 3
    • 84896694664 scopus 로고    scopus 로고
    • Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact
    • E.M.Trecarichi, M.Tumbarello Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer:current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27:200–210.
    • (2014) Curr Opin Infect Dis , vol.27 , pp. 200-210
    • Trecarichi, E.M.1    Tumbarello, M.2
  • 4
    • 84879180123 scopus 로고    scopus 로고
    • Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance
    • E.Montassier, E.Batard, T.Gastinne,. Recent changes in bacteremia in patients with cancer:a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32:841–850.
    • (2013) Eur J Clin Microbiol Infect Dis , vol.32 , pp. 841-850
    • Montassier, E.1    Batard, E.2    Gastinne, T.3
  • 5
    • 84902769829 scopus 로고    scopus 로고
    • Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies
    • L.Pagano, M.Caira, E.M.Trecarichi,. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerging Infect Dis. 2014;20:1235–1236.
    • (2014) Emerging Infect Dis , vol.20 , pp. 1235-1236
    • Pagano, L.1    Caira, M.2    Trecarichi, E.M.3
  • 6
    • 79951816939 scopus 로고    scopus 로고
    • Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america
    • A.G.Freifeld, E.J.Bow, K.A.Sepkowitz,. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52:e56–e93.
    • (2011) Clin Infect Dis , vol.52 , pp. e56-e93
    • Freifeld, A.G.1    Bow, E.J.2    Sepkowitz, K.A.3
  • 7
    • 84928546728 scopus 로고    scopus 로고
    • Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey
    • E.M.Trecarichi, L.Pagano, A.Candoni,. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies:an Italian multicentre prospective survey. Clin Microbiol Infect. 2015;21:337–343.
    • (2015) Clin Microbiol Infect , vol.21 , pp. 337-343
    • Trecarichi, E.M.1    Pagano, L.2    Candoni, A.3
  • 8
    • 24344471724 scopus 로고    scopus 로고
    • Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia
    • G.Bucaneve, A.Micozzi, F.Menichetti,. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987.
    • (2005) N Engl J Med , vol.353 , pp. 977-987
    • Bucaneve, G.1    Micozzi, A.2    Menichetti, F.3
  • 9
    • 77953685297 scopus 로고    scopus 로고
    • Escherichia coli resistance to quinolones at a comprehensive cancer center
    • C.N.Mihu, P.R.Rhomberg, R.N.Jones,. Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis. 2010;67:266–269.
    • (2010) Diagn Microbiol Infect Dis , vol.67 , pp. 266-269
    • Mihu, C.N.1    Rhomberg, P.R.2    Jones, R.N.3
  • 10
    • 77950261972 scopus 로고    scopus 로고
    • Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome
    • C.Gudiol, L.Calatayud, C.Garcia-Vidal,. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients:clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65:333–341.
    • (2010) J Antimicrob Chemother , vol.65 , pp. 333-341
    • Gudiol, C.1    Calatayud, L.2    Garcia-Vidal, C.3
  • 11
    • 84857375975 scopus 로고    scopus 로고
    • Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy
    • C.-I.Kang, D.R.Chung, K.S.Ko,. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol. 2012;91:115–121.
    • (2012) Ann Hematol , vol.91 , pp. 115-121
    • Kang, C.-I.1    Chung, D.R.2    Ko, K.S.3
  • 12
    • 84877065762 scopus 로고    scopus 로고
    • Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome
    • S.-H.Kim, J.-C.Kwon, S.-M.Choi,. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever:factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol. 2013;92:533–541.
    • (2013) Ann Hematol , vol.92 , pp. 533-541
    • Kim, S.-H.1    Kwon, J.-C.2    Choi, S.-M.3
  • 13
    • 34250188146 scopus 로고    scopus 로고
    • Epidemiology of bacteremia and factors associated with multi-drug-resistant Gram-negative bacteremia in hematopoietic stem cell transplant recipients
    • A.L.Oliveira, M.de Souza, V.M.H.Carvalho-Dias,. Epidemiology of bacteremia and factors associated with multi-drug-resistant Gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2007;39:775–781.
    • (2007) Bone Marrow Transplant , vol.39 , pp. 775-781
    • Oliveira, A.L.1    de Souza, M.2    Carvalho-Dias, V.M.H.3
  • 14
    • 84885428877 scopus 로고    scopus 로고
    • Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer
    • Y.E.Ha, C.-I.Kang, M.K.Cha,. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. 2013;42:403–409.
    • (2013) Int J Antimicrob Agents , vol.42 , pp. 403-409
    • Ha, Y.E.1    Kang, C.-I.2    Cha, M.K.3
  • 15
    • 84876706549 scopus 로고    scopus 로고
    • Factors influencing the early mortality in haematological malignancy patients with nosocomial Gram negative bacilli bacteraemia: a retrospective analysis of 154 cases
    • G.Metan, H.Demiraslan, L.G.Kaynar,. Factors influencing the early mortality in haematological malignancy patients with nosocomial Gram negative bacilli bacteraemia:a retrospective analysis of 154 cases. Braz J Infect Dis. 2013;17:143–149.
    • (2013) Braz J Infect Dis , vol.17 , pp. 143-149
    • Metan, G.1    Demiraslan, H.2    Kaynar, L.G.3
  • 16
    • 84983565508 scopus 로고    scopus 로고
    • The changing epidemiology of blood stream infections and resistance in haematopoietic stem cell transplantation recipients
    • M.Yemişen, İ.İ.Balkan, A.Salihoğlu,. The changing epidemiology of blood stream infections and resistance in haematopoietic stem cell transplantation recipients. Turk J Haematol. 2015. [Epub ahead of print]. doi:10.4274/tjh.2014.0378.
    • (2015) Turk J Haematol
    • Yemişen, M.1    Balkan, İ.İ.2    Salihoğlu, A.3
  • 17
    • 22144433025 scopus 로고    scopus 로고
    • Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection
    • E.P.Hyle, A.D.Lipworth, T.E.Zaoutis,. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae:variability by site of infection. Arch Intern Med. 2005;165:1375–1380.
    • (2005) Arch Intern Med , vol.165 , pp. 1375-1380
    • Hyle, E.P.1    Lipworth, A.D.2    Zaoutis, T.E.3
  • 18
    • 84863342359 scopus 로고    scopus 로고
    • Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States
    • Y.S.Park, J.M.Adams-Haduch, K.A.Shutt,. Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother. 2012;56:1870–1876.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 1870-1876
    • Park, Y.S.1    Adams-Haduch, J.M.2    Shutt, K.A.3
  • 19
    • 84893488813 scopus 로고    scopus 로고
    • Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups
    • M.Castanheira, S.E.Farrell, K.M.Krause,. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother. 2013;58:833–838.
    • (2013) Antimicrob Agents Chemother , vol.58 , pp. 833-838
    • Castanheira, M.1    Farrell, S.E.2    Krause, K.M.3
  • 20
    • 84873021014 scopus 로고    scopus 로고
    • Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters
    • N.-Y.Lee, C.-C.Lee, W.-H.Huang,. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae:MIC matters. Clin Infect Dis. 2013;56:488–495.
    • (2013) Clin Infect Dis , vol.56 , pp. 488-495
    • Lee, N.-Y.1    Lee, C.-C.2    Huang, W.-H.3
  • 21
    • 84928879624 scopus 로고    scopus 로고
    • Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia
    • P.D.Tamma, J.H.Han, C.Rock,. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis. 2015;60:1319–1325.
    • (2015) Clin Infect Dis , vol.60 , pp. 1319-1325
    • Tamma, P.D.1    Han, J.H.2    Rock, C.3
  • 22
    • 0035189967 scopus 로고    scopus 로고
    • Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae
    • K.S.Thomson, E.S.Moland Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2001;45:3548–3554.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 3548-3554
    • Thomson, K.S.1    Moland, E.S.2
  • 23
    • 59649115459 scopus 로고    scopus 로고
    • AmpC beta-lactamases
    • G.A.Jacoby AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161–182.
    • (2009) Clin Microbiol Rev , vol.22 , pp. 161-182
    • Jacoby, G.A.1
  • 24
    • 0025938759 scopus 로고
    • Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy
    • J.W.Chow, M.J.Fine, D.M.Shlaes,. Enterobacter bacteremia:clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585–590.
    • (1991) Ann Intern Med , vol.115 , pp. 585-590
    • Chow, J.W.1    Fine, M.J.2    Shlaes, D.M.3
  • 25
    • 40549134482 scopus 로고    scopus 로고
    • Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use
    • S.-H.Choi, J.E.Lee, S.J.Park,. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase:implications for antibiotic use. Antimicrob Agents Chemother. 2008;52:995–1000.
    • (2008) Antimicrob Agents Chemother , vol.52 , pp. 995-1000
    • Choi, S.-H.1    Lee, J.E.2    Park, S.J.3
  • 26
    • 84962514723 scopus 로고    scopus 로고
    • Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies
    • Ö.Kara, P.Zarakolu, S.Aşçioğlu,. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infect Dis (Lond). 2015;47:686–693.
    • (2015) Infect Dis (Lond) , vol.47 , pp. 686-693
    • Kara, Ö.1    Zarakolu, P.2    Aşçioğlu, S.3
  • 27
    • 12344334529 scopus 로고    scopus 로고
    • Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase
    • C.-I.Kang, H.Pai, S.-H.Kim,. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase. J Antimicrob Chemother. 2004;54:1130–1133.
    • (2004) J Antimicrob Chemother , vol.54 , pp. 1130-1133
    • Kang, C.-I.1    Pai, H.2    Kim, S.-H.3
  • 28
    • 84883238476 scopus 로고    scopus 로고
    • The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae
    • P.D.Tamma, S.C.T.Girdwood, R.Gopaul,. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57:781–788.
    • (2013) Clin Infect Dis , vol.57 , pp. 781-788
    • Tamma, P.D.1    Girdwood, S.C.T.2    Gopaul, R.3
  • 29
    • 84954537407 scopus 로고    scopus 로고
    • Cefepime therapy for monomicrobial enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates
    • N.-Y.Lee, C.-C.Lee, C.-W.Li,. Cefepime therapy for monomicrobial enterobacter cloacae bacteremia:unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates. Antimicrob Agents Chemother. 2015;59:7558–7563.
    • (2015) Antimicrob Agents Chemother , vol.59 , pp. 7558-7563
    • Lee, N.-Y.1    Lee, C.-C.2    Li, C.-W.3
  • 30
    • 47249127343 scopus 로고    scopus 로고
    • Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia
    • M.Marcos, A.Iñurrieta, A.Soriano,. Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. J Antimicrob Chemother. 2008;62:397–403.
    • (2008) J Antimicrob Chemother , vol.62 , pp. 397-403
    • Marcos, M.1    Iñurrieta, A.2    Soriano, A.3
  • 31
    • 84959909713 scopus 로고    scopus 로고
    • Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis
    • P.N.A.Harris, J.Y.Wei, A.W.Shen,. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species:a systematic review with meta-analysis. J Antimicrob Chemother. 2016;71:296–306.
    • (2016) J Antimicrob Chemother , vol.71 , pp. 296-306
    • Harris, P.N.A.1    Wei, J.Y.2    Shen, A.W.3
  • 32
    • 84898867259 scopus 로고    scopus 로고
    • The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies
    • M.J.Satlin, S.G.Jenkins, T.J.Walsh The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58:1274–1283.
    • (2014) Clin Infect Dis , vol.58 , pp. 1274-1283
    • Satlin, M.J.1    Jenkins, S.G.2    Walsh, T.J.3
  • 33
    • 84922330557 scopus 로고    scopus 로고
    • Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy
    • C.Girmenia, G.M.Rossolini, A.Piciocchi,. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients:a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015;50:282–288.
    • (2015) Bone Marrow Transplant , vol.50 , pp. 282-288
    • Girmenia, C.1    Rossolini, G.M.2    Piciocchi, A.3
  • 34
    • 84930486688 scopus 로고    scopus 로고
    • Global spread of carbapenemase-producing Enterobacteriaceae
    • P.Nordmann, T.Naas, L.Poirel Global spread of carbapenemase-producing Enterobacteriaceae. Emerging Infect Dis. 2011;17:1791–1798.
    • (2011) Emerging Infect Dis , vol.17 , pp. 1791-1798
    • Nordmann, P.1    Naas, T.2    Poirel, L.3
  • 35
    • 84942240891 scopus 로고    scopus 로고
    • Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance
    • J.D.D.Pitout, P.Nordmann, L.Poirel Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59:5873–5884.
    • (2015) Antimicrob Agents Chemother , vol.59 , pp. 5873-5884
    • Pitout, J.D.D.1    Nordmann, P.2    Poirel, L.3
  • 36
    • 67651085441 scopus 로고    scopus 로고
    • Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns
    • K.Hussein, H.Sprecher, T.Mashiach,. Carbapenem resistance among Klebsiella pneumoniae isolates:risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol. 2009;30:666–671.
    • (2009) Infect Control Hosp Epidemiol , vol.30 , pp. 666-671
    • Hussein, K.1    Sprecher, H.2    Mashiach, T.3
  • 37
    • 84875386814 scopus 로고    scopus 로고
    • Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniae
    • K.Hussein, A.Raz-Pasteur, R.Finkelstein,. Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect. 2013;83:307–313.
    • (2013) J Hosp Infect , vol.83 , pp. 307-313
    • Hussein, K.1    Raz-Pasteur, A.2    Finkelstein, R.3
  • 38
    • 73449096797 scopus 로고    scopus 로고
    • Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae
    • L.B.Gasink, P.H.Edelstein, E.Lautenbach,. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180–1185.
    • (2009) Infect Control Hosp Epidemiol , vol.30 , pp. 1180-1185
    • Gasink, L.B.1    Edelstein, P.H.2    Lautenbach, E.3
  • 39
    • 84982831231 scopus 로고    scopus 로고
    • M.J.Satlin, N.Cohen, K.C.Ma,. Prevalence, risk factors, and outcomes of bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies [abstract #434]. Poster presented at:IDWeek; 2014 Oct 9; Philadelphia, PA.
    • Satlin, M.J.1    Cohen, N.2    Ma, K.C.3
  • 40
    • 84921766986 scopus 로고    scopus 로고
    • Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients
    • M.P.Freire, L.C.Pierrotti, H.H.C.Filho,. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients. Eur J Clin Microbiol Infect Dis. 2015;34:277–286.
    • (2015) Eur J Clin Microbiol Infect Dis , vol.34 , pp. 277-286
    • Freire, M.P.1    Pierrotti, L.C.2    Filho, H.H.C.3
  • 41
    • 84904554359 scopus 로고    scopus 로고
    • Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival
    • I.I.Balkan, G.Aygün, S.Aydın,. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae:treatment and survival. Int J Infect Dis. 2014;26:51–56.
    • (2014) Int J Infect Dis , vol.26 , pp. 51-56
    • Balkan, I.I.1    Aygün, G.2    Aydın, S.3
  • 42
    • 84898606478 scopus 로고    scopus 로고
    • In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy
    • K.Phe, Y.Lee, P.M.McDaneld,. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58:2740–2746.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 2740-2746
    • Phe, K.1    Lee, Y.2    McDaneld, P.M.3
  • 43
    • 0015786342 scopus 로고
    • Advances in the management of Pseudomonas aeruginosa infections in cancer patients
    • G.P.Bodey, V.Rodriguez Advances in the management of Pseudomonas aeruginosa infections in cancer patients. Eur J Cancer. 1973;9:435–441.
    • (1973) Eur J Cancer , vol.9 , pp. 435-441
    • Bodey, G.P.1    Rodriguez, V.2
  • 44
    • 84871618339 scopus 로고    scopus 로고
    • High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality
    • A.Capone, M.Giannella, D.Fortini,. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19:E23–E30.
    • (2013) Clin Microbiol Infect , vol.19 , pp. E23-E30
    • Capone, A.1    Giannella, M.2    Fortini, D.3
  • 45
    • 80051692552 scopus 로고    scopus 로고
    • Efficacy and safety of tigecycline: a systematic review and meta-analysis
    • D.Yahav, A.Lador, M.Paul,. Efficacy and safety of tigecycline:a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1963–1971.
    • (2011) J Antimicrob Chemother , vol.66 , pp. 1963-1971
    • Yahav, D.1    Lador, A.2    Paul, M.3
  • 47
    • 0022219276 scopus 로고
    • Pseudomonas bacteremia. Retrospective analysis of 410 episodes
    • G.P.Bodey, L.Jadeja, L.Elting Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985;145:1621–1629.
    • (1985) Arch Intern Med , vol.145 , pp. 1621-1629
    • Bodey, G.P.1    Jadeja, L.2    Elting, L.3
  • 48
    • 84872180720 scopus 로고    scopus 로고
    • Population-based incidence of carbapenem-resistant Klebsiella pneumoniae along the continuum of care, Los Angeles County
    • P.Marquez, D.Terashita, D.Dassey,. Population-based incidence of carbapenem-resistant Klebsiella pneumoniae along the continuum of care, Los Angeles County. Infect Control Hosp Epidemiol. 2013;34:144–150.
    • (2013) Infect Control Hosp Epidemiol , vol.34 , pp. 144-150
    • Marquez, P.1    Terashita, D.2    Dassey, D.3
  • 49
    • 84871635409 scopus 로고    scopus 로고
    • Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998–2010
    • G.V.Sanchez, R.N.Master, R.B.Clark,. Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998–2010. Emerging Infect Dis. 2013;19:133–136.
    • (2013) Emerging Infect Dis , vol.19 , pp. 133-136
    • Sanchez, G.V.1    Master, R.N.2    Clark, R.B.3
  • 50
    • 68749111844 scopus 로고    scopus 로고
    • A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function
    • W.M.Sweileh A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function. Fundam Clin Pharmacol. 2009;23:515–520.
    • (2009) Fundam Clin Pharmacol , vol.23 , pp. 515-520
    • Sweileh, W.M.1
  • 51
    • 84905985310 scopus 로고    scopus 로고
    • Once-daily dosed gentamicin is more nephrotoxic than once-daily dosed tobramycin in clinically infected patients
    • E.Van Maarseveen, M.-C.van Buul-Gast, R.Abdoellakhan,. Once-daily dosed gentamicin is more nephrotoxic than once-daily dosed tobramycin in clinically infected patients. J Antimicrob Chemother. 2014;69:2581–2583.
    • (2014) J Antimicrob Chemother , vol.69 , pp. 2581-2583
    • Van Maarseveen, E.1    van Buul-Gast, M.-C.2    Abdoellakhan, R.3
  • 52
    • 84896940320 scopus 로고    scopus 로고
    • Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems
    • G.L.Daikos, S.Tsaousi, L.S.Tzouvelekis,. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections:lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–2328.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 2322-2328
    • Daikos, G.L.1    Tsaousi, S.2    Tzouvelekis, L.S.3
  • 53
    • 84858627056 scopus 로고    scopus 로고
    • Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens
    • Z.A.Qureshi, D.L.Paterson, B.A.Potoski,. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae:superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108–2113.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 2108-2113
    • Qureshi, Z.A.1    Paterson, D.L.2    Potoski, B.A.3
  • 54
    • 84866072596 scopus 로고    scopus 로고
    • Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy
    • M.Tumbarello, P.Viale, C.Viscoli,. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae:importance of combination therapy. Clin Infect Dis. 2012;55:943–950.
    • (2012) Clin Infect Dis , vol.55 , pp. 943-950
    • Tumbarello, M.1    Viale, P.2    Viscoli, C.3
  • 55
    • 84943751309 scopus 로고    scopus 로고
    • Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study–authors’ response
    • M.Tumbarello, P.Viale, M.Bassetti,. Infections caused by KPC-producing Klebsiella pneumoniae:differences in therapy and mortality in a multicentre study–authors’ response. J Antimicrob Chemother. 2015;70:2922.
    • (2015) J Antimicrob Chemother , vol.70 , pp. 2922
    • Tumbarello, M.1    Viale, P.2    Bassetti, M.3
  • 56
    • 84929587395 scopus 로고    scopus 로고
    • Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains
    • M.Castanheira, J.C.Mills, S.E.Costello,. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains. Antimicrob Agents Chemother. 2015;59:3509–3517.
    • (2015) Antimicrob Agents Chemother , vol.59 , pp. 3509-3517
    • Castanheira, M.1    Mills, J.C.2    Costello, S.E.3
  • 57
    • 84940449628 scopus 로고    scopus 로고
    • Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections
    • J.L.Liscio, M.V.Mahoney, E.B.Hirsch Ceftolozane/tazobactam and ceftazidime/avibactam:two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015;46:266–271.
    • (2015) Int J Antimicrob Agents , vol.46 , pp. 266-271
    • Liscio, J.L.1    Mahoney, M.V.2    Hirsch, E.B.3
  • 58
    • 0015800331 scopus 로고
    • Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer
    • S.C.Schimpff, W.H.Greene, V.M.Young,. Pseudomonas septicemia:incidence, epidemiology, prevention and therapy in patients with advanced cancer. Eur J Cancer. 1973;9:449–455.
    • (1973) Eur J Cancer , vol.9 , pp. 449-455
    • Schimpff, S.C.1    Greene, W.H.2    Young, V.M.3
  • 60
    • 0036498656 scopus 로고    scopus 로고
    • Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?
    • D.M.Livermore Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa:our worst nightmare? Clin Infect Dis. 2002;34:634–640.
    • (2002) Clin Infect Dis , vol.34 , pp. 634-640
    • Livermore, D.M.1
  • 61
    • 0034723745 scopus 로고    scopus 로고
    • Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes
    • I.Chatzinikolaou, D.Abi-Said, G.P.Bodey,. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer:retrospective analysis of 245 episodes. Arch Intern Med. 2000;160:501–509.
    • (2000) Arch Intern Med , vol.160 , pp. 501-509
    • Chatzinikolaou, I.1    Abi-Said, D.2    Bodey, G.P.3
  • 62
    • 0033059706 scopus 로고    scopus 로고
    • Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents
    • Y.Carmeli, N.Troillet, G.M.Eliopoulos,. Emergence of antibiotic-resistant Pseudomonas aeruginosa:comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379–1382.
    • (1999) Antimicrob Agents Chemother , vol.43 , pp. 1379-1382
    • Carmeli, Y.1    Troillet, N.2    Eliopoulos, G.M.3
  • 63
    • 0028274211 scopus 로고
    • Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group
    • M.P.Fink, D.R.Snydman, M.S.Niederman,. Treatment of severe pneumonia in hospitalized patients:results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother. 1994;38:547–557.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 547-557
    • Fink, M.P.1    Snydman, D.R.2    Niederman, M.S.3
  • 64
    • 10744230588 scopus 로고    scopus 로고
    • Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study
    • G.Zanetti, F.Bally, G.Greub,. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients:a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother. 2003;47:3442–3447.
    • (2003) Antimicrob Agents Chemother , vol.47 , pp. 3442-3447
    • Zanetti, G.1    Bally, F.2    Greub, G.3
  • 65
    • 84455192457 scopus 로고    scopus 로고
    • Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa
    • G.L.Drusano, R.A.Bonomo, N.Bahniuk,. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:231–242.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 231-242
    • Drusano, G.L.1    Bonomo, R.A.2    Bahniuk, N.3
  • 66
    • 77952607034 scopus 로고    scopus 로고
    • The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression
    • A.Louie, C.Grasso, N.Bahniuk,. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother. 2010;54:2646–2654.
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 2646-2654
    • Louie, A.1    Grasso, C.2    Bahniuk, N.3
  • 67
    • 77952650628 scopus 로고    scopus 로고
    • Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance
    • A.Louie, A.Bied, C.Fregeau,. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother. 2010;54:2638–2645.
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 2638-2645
    • Louie, A.1    Bied, A.2    Fregeau, C.3
  • 68
    • 33846442436 scopus 로고    scopus 로고
    • Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy
    • T.P.Lodise, B.Lomaestro, G.L.Drusano Piperacillin-tazobactam for Pseudomonas aeruginosa infection:clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44:357–363.
    • (2007) Clin Infect Dis , vol.44 , pp. 357-363
    • Lodise, T.P.1    Lomaestro, B.2    Drusano, G.L.3
  • 69
    • 84879017246 scopus 로고    scopus 로고
    • Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections
    • K.A.Bauer, J.E.West, J.M.O’Brien,. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013;57:2907–2912.
    • (2013) Antimicrob Agents Chemother , vol.57 , pp. 2907-2912
    • Bauer, K.A.1    West, J.E.2    O’Brien, J.M.3
  • 70
    • 84887449664 scopus 로고    scopus 로고
    • Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012)
    • D.J.Farrell, R.K.Flamm, H.S.Sader,. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012). Antimicrob Agents Chemother. 2013;57:6305–6310.
    • (2013) Antimicrob Agents Chemother , vol.57 , pp. 6305-6310
    • Farrell, D.J.1    Flamm, R.K.2    Sader, H.S.3
  • 71
    • 84934963355 scopus 로고    scopus 로고
    • Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia
    • H.S.Sader, M.Castanheira, R.K.Flamm,. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents. 2015;46:53–59.
    • (2015) Int J Antimicrob Agents , vol.46 , pp. 53-59
    • Sader, H.S.1    Castanheira, M.2    Flamm, R.K.3
  • 72
    • 47949089607 scopus 로고    scopus 로고
    • Acinetobacter baumannii: emergence of a successful pathogen
    • A.Y.Peleg, H.Seifert, D.L.Paterson Acinetobacter baumannii:emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538–582.
    • (2008) Clin Microbiol Rev , vol.21 , pp. 538-582
    • Peleg, A.Y.1    Seifert, H.2    Paterson, D.L.3
  • 73
    • 84908506410 scopus 로고    scopus 로고
    • Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study
    • S.K.Seo, K.Xiao, Y.-T.Huang,. Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients:a 12-year single institution study. J Infect. 2014;69:341–351.
    • (2014) J Infect , vol.69 , pp. 341-351
    • Seo, S.K.1    Xiao, K.2    Huang, Y.-T.3
  • 74
    • 33747625237 scopus 로고    scopus 로고
    • Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa
    • R.A.Bonomo, D.Szabo Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43:S49–S56.
    • (2006) Clin Infect Dis , vol.43 , pp. S49-S56
    • Bonomo, R.A.1    Szabo, D.2
  • 75
    • 84932115203 scopus 로고    scopus 로고
    • Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options
    • M.Castanheira, R.E.Mendes, R.N.Jones Update on Acinetobacter species:mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis. 2014;59:S367–S373.
    • (2014) Clin Infect Dis , vol.59 , pp. S367-S373
    • Castanheira, M.1    Mendes, R.E.2    Jones, R.N.3
  • 77
    • 80053448027 scopus 로고    scopus 로고
    • Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality
    • M.Turkoglu, E.Mirza, O.G.Tunçcan,. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit:risk factors and impact on mortality. J Crit Care. 2011;26:460–467.
    • (2011) J Crit Care , vol.26 , pp. 460-467
    • Turkoglu, M.1    Mirza, E.2    Tunçcan, O.G.3
  • 78
    • 84862902944 scopus 로고    scopus 로고
    • Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy
    • Y.J.Kim, S.I.Kim, K.-W.Hong,. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia:impact of appropriate antimicrobial therapy. J Korean Med Sci. 2012;27:471–475.
    • (2012) J Korean Med Sci , vol.27 , pp. 471-475
    • Kim, Y.J.1    Kim, S.I.2    Hong, K.-W.3
  • 79
    • 84898007596 scopus 로고    scopus 로고
    • Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia
    • T.Khawcharoenporn, N.Pruetpongpun, P.Tiamsak,. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents. 2014;43:378–382.
    • (2014) Int J Antimicrob Agents , vol.43 , pp. 378-382
    • Khawcharoenporn, T.1    Pruetpongpun, N.2    Tiamsak, P.3
  • 80
    • 84928887610 scopus 로고    scopus 로고
    • A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections
    • D.J.Ritchie, A.Garavaglia-Wilson A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014;59:S374–S380.
    • (2014) Clin Infect Dis , vol.59 , pp. S374-S380
    • Ritchie, D.J.1    Garavaglia-Wilson, A.2
  • 81
    • 84949667186 scopus 로고    scopus 로고
    • Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
    • Y.-T.Chang, C.-Y.Lin, Y.-H.Chen,. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015;6:893.
    • (2015) Front Microbiol , vol.6 , pp. 893
    • Chang, Y.-T.1    Lin, C.-Y.2    Chen, Y.-H.3
  • 82
    • 84855650410 scopus 로고    scopus 로고
    • Stenotrophomonas maltophilia: an emerging global opportunistic pathogen
    • J.S.Brooke Stenotrophomonas maltophilia:an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25:2–41.
    • (2012) Clin Microbiol Rev , vol.25 , pp. 2-41
    • Brooke, J.S.1
  • 83
    • 84958155803 scopus 로고    scopus 로고
    • Prevalence of resistant Gram-Negative Bacilli in bloodstream infection in febrile neutropenia patients undergoing hematopoietic stem cell transplantation: a single center retrospective cohort study
    • L.Wang, Y.Wang, X.Fan,. Prevalence of resistant Gram-Negative Bacilli in bloodstream infection in febrile neutropenia patients undergoing hematopoietic stem cell transplantation:a single center retrospective cohort study. Medicine (Baltimore). 2015;94:e1931.
    • (2015) Medicine (Baltimore) , vol.94 , pp. e1931
    • Wang, L.1    Wang, Y.2    Fan, X.3
  • 84
    • 80054083841 scopus 로고    scopus 로고
    • Predictors of catheter-related gram-negative bacilli bacteraemia among cancer patients
    • J.Cairo, R.Hachem, G.Rangaraj,. Predictors of catheter-related gram-negative bacilli bacteraemia among cancer patients. Clin Microbiol Infect. 2011;17:1711–1716.
    • (2011) Clin Microbiol Infect , vol.17 , pp. 1711-1716
    • Cairo, J.1    Hachem, R.2    Rangaraj, G.3
  • 85
    • 16644397823 scopus 로고    scopus 로고
    • Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia
    • C.-H.Lai, C.-Y.Chi, H.-P.Chen,. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect. 2004;37:350–358.
    • (2004) J Microbiol Immunol Infect , vol.37 , pp. 350-358
    • Lai, C.-H.1    Chi, C.-Y.2    Chen, H.-P.3
  • 86
    • 33746606840 scopus 로고    scopus 로고
    • Which patient is a candidate for empirical therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital
    • G.Metan, M.Hayran, G.Hascelik,. Which patient is a candidate for empirical therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital. Scand J Infect Dis. 2006;38:527–531.
    • (2006) Scand J Infect Dis , vol.38 , pp. 527-531
    • Metan, G.1    Hayran, M.2    Hascelik, G.3
  • 87
    • 0038071628 scopus 로고    scopus 로고
    • Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study
    • A.Apisarnthanarak, J.L.Mayfield, T.Garison,. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients:a case-control study. Infect Control Hosp Epidemiol. 2003;24:269–274.
    • (2003) Infect Control Hosp Epidemiol , vol.24 , pp. 269-274
    • Apisarnthanarak, A.1    Mayfield, J.L.2    Garison, T.3
  • 88
    • 84887594809 scopus 로고    scopus 로고
    • Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients
    • H.Demiraslan, M.Sevim, Ç.Pala,. Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients. Int J Hematol. 2013;97:414–420.
    • (2013) Int J Hematol , vol.97 , pp. 414-420
    • Demiraslan, H.1    Sevim, M.2    Pala, Ç.3
  • 89
    • 0034457193 scopus 로고    scopus 로고
    • Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies
    • A.Micozzi, M.Venditti, M.Monaco,. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis. 2000;31:705–711.
    • (2000) Clin Infect Dis , vol.31 , pp. 705-711
    • Micozzi, A.1    Venditti, M.2    Monaco, M.3
  • 90
    • 84928658419 scopus 로고    scopus 로고
    • Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations
    • S.-Y.Cho, D.-G.Lee, S.-M.Choi,. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies:a retrospective study and in vitro activities of antimicrobial combinations. BMC Infect Dis. 2015;15:69.
    • (2015) BMC Infect Dis , vol.15 , pp. 69
    • Cho, S.-Y.1    Lee, D.-G.2    Choi, S.-M.3
  • 91
    • 77952597308 scopus 로고    scopus 로고
    • Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections
    • D.J.Farrell, H.S.Sader, R.N.Jones Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010;54:2735–2737.
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 2735-2737
    • Farrell, D.J.1    Sader, H.S.2    Jones, R.N.3
  • 92
    • 84891499399 scopus 로고    scopus 로고
    • Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections
    • Y.L.Wang, M.R.Scipione, Y.Dubrovskaya,. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58:176–182.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 176-182
    • Wang, Y.L.1    Scipione, M.R.2    Dubrovskaya, Y.3
  • 93
    • 84891530851 scopus 로고    scopus 로고
    • Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?
    • S.Y.Cho, C.-I.Kang, J.Kim,. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother. 2014;58:581–583.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 581-583
    • Cho, S.Y.1    Kang, C.-I.2    Kim, J.3
  • 94
    • 84897997775 scopus 로고    scopus 로고
    • Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY antimicrobial surveillance program, 2009-2012
    • H.S.Sader, D.J.Farrell, R.K.Flamm,. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals:results from the SENTRY antimicrobial surveillance program, 2009-2012. Int J Antimicrob Agents. 2014;43:328–334.
    • (2014) Int J Antimicrob Agents , vol.43 , pp. 328-334
    • Sader, H.S.1    Farrell, D.J.2    Flamm, R.K.3
  • 95
    • 84962069288 scopus 로고    scopus 로고
    • Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections
    • E.Hand, H.Davis, T.Kim,. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J Antimicrob Chemother. 2016;71:1071–1075.
    • (2016) J Antimicrob Chemother , vol.71 , pp. 1071-1075
    • Hand, E.1    Davis, H.2    Kim, T.3
  • 96
    • 84925230536 scopus 로고    scopus 로고
    • Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria
    • M.Ruhnke, R.Arnold, P.Gastmeier Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol. 2014;15:e606–e619.
    • (2014) Lancet Oncol , vol.15 , pp. e606-e619
    • Ruhnke, M.1    Arnold, R.2    Gastmeier, P.3
  • 97
    • 84941073950 scopus 로고    scopus 로고
    • The prevention and management of infections due to multidrug resistant organisms in haematology patients
    • J.A.Trubiano, L.J.Worth, K.A.Thursky,. The prevention and management of infections due to multidrug resistant organisms in haematology patients. Br J Clin Pharmacol. 2015;79:195–207.
    • (2015) Br J Clin Pharmacol , vol.79 , pp. 195-207
    • Trubiano, J.A.1    Worth, L.J.2    Thursky, K.A.3
  • 98
    • 84890161363 scopus 로고    scopus 로고
    • ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients
    • E.Tacconelli, M.A.Cataldo, S.J.Dancer,. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20:1–55.
    • (2014) Clin Microbiol Infect , vol.20 , pp. 1-55
    • Tacconelli, E.1    Cataldo, M.A.2    Dancer, S.J.3
  • 99
    • 67649717007 scopus 로고    scopus 로고
    • Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae
    • S.Kochar, T.Sheard, R.Sharma,. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2009;30:447–452.
    • (2009) Infect Control Hosp Epidemiol , vol.30 , pp. 447-452
    • Kochar, S.1    Sheard, T.2    Sharma, R.3
  • 100
    • 77952163360 scopus 로고    scopus 로고
    • Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection
    • D.Ben-David, Y.Maor, N.Keller,. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol. 2010;31:620–626.
    • (2010) Infect Control Hosp Epidemiol , vol.31 , pp. 620-626
    • Ben-David, D.1    Maor, Y.2    Keller, N.3
  • 101
    • 84888434099 scopus 로고    scopus 로고
    • Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients
    • Y.Fukuta, R.R.Muder, M.E.Agha,. Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am J Infect Control. 2013;41:1249–1252.
    • (2013) Am J Infect Control , vol.41 , pp. 1249-1252
    • Fukuta, Y.1    Muder, R.R.2    Agha, M.E.3
  • 102
    • 84889781345 scopus 로고    scopus 로고
    • The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients
    • I.C.Gyssens, W.V.Kern, D.M.Livermore ECIL-4, A Joint Venture of EBMT, EORTC, ICHS and ESGICH of ESCMID. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica. 2013;98:1821–1825.
    • (2013) Haematologica , vol.98 , pp. 1821-1825
    • Gyssens, I.C.1    Kern, W.V.2    Livermore, D.M.3
  • 103
    • 84888416637 scopus 로고    scopus 로고
    • Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: a prospective controlled trial
    • I.Oren, H.Sprecher, R.Finkelstein,. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment:a prospective controlled trial. Am J Infect Control. 2013;41:1167–1172.
    • (2013) Am J Infect Control , vol.41 , pp. 1167-1172
    • Oren, I.1    Sprecher, H.2    Finkelstein, R.3
  • 104
    • 84879006895 scopus 로고    scopus 로고
    • Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit
    • T.Halaby, N.Al Naiemi, J.Kluytmans,. Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother. 2013;57:3224–3229.
    • (2013) Antimicrob Agents Chemother , vol.57 , pp. 3224-3229
    • Halaby, T.1    Al Naiemi, N.2    Kluytmans, J.3
  • 105
    • 84889080918 scopus 로고    scopus 로고
    • Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience
    • C.Lübbert, S.Faucheux, D.Becker-Rux,. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae:a single-centre experience. Int J Antimicrob Agents. 2013;42:565–570.
    • (2013) Int J Antimicrob Agents , vol.42 , pp. 565-570
    • Lübbert, C.1    Faucheux, S.2    Becker-Rux, D.3
  • 106
    • 78650262379 scopus 로고    scopus 로고
    • Orally administered colistin leads to colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum β-lactamase-producing enterobacteria in hospitalised newborns
    • V.Strenger, T.Gschliesser, A.Grisold,. Orally administered colistin leads to colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum β-lactamase-producing enterobacteria in hospitalised newborns. Int J Antimicrob Agents. 2011;37:67–69.
    • (2011) Int J Antimicrob Agents , vol.37 , pp. 67-69
    • Strenger, V.1    Gschliesser, T.2    Grisold, A.3
  • 107
    • 80052434891 scopus 로고    scopus 로고
    • SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state
    • T.Zuckerman, N.Benyamini, H.Sprecher,. SCT in patients with carbapenem resistant Klebsiella pneumoniae:a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant. 2011;46:1226–1230.
    • (2011) Bone Marrow Transplant , vol.46 , pp. 1226-1230
    • Zuckerman, T.1    Benyamini, N.2    Sprecher, H.3
  • 108
    • 84934325671 scopus 로고    scopus 로고
    • A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies
    • M.J.G.T.Vehreschild, A.Hamprecht, L.Peterson,. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother. 2014;69:3387–3392.
    • (2014) J Antimicrob Chemother , vol.69 , pp. 3387-3392
    • Vehreschild, M.J.G.T.1    Hamprecht, A.2    Peterson, L.3
  • 109
    • 84949084903 scopus 로고    scopus 로고
    • Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies
    • P.Cornejo-Juárez, J.A.Suárez-Cuenca, P.Volkow-Fernández,. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies. Support Care Cancer. 2016;24:253–259.
    • (2016) Support Care Cancer , vol.24 , pp. 253-259
    • Cornejo-Juárez, P.1    Suárez-Cuenca, J.A.2    Volkow-Fernández, P.3
  • 110
    • 84923228267 scopus 로고    scopus 로고
    • Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation
    • L.Nesher, K.V.I.Rolston, D.P.Shah,. Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2015;17:33–38.
    • (2015) Transpl Infect Dis , vol.17 , pp. 33-38
    • Nesher, L.1    Rolston, K.V.I.2    Shah, D.P.3
  • 111
    • 84942084780 scopus 로고    scopus 로고
    • Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing
    • R.Banerjee, C.B.Teng, S.A.Cunningham,. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. 2015;61:1071–1080.
    • (2015) Clin Infect Dis , vol.61 , pp. 1071-1080
    • Banerjee, R.1    Teng, C.B.2    Cunningham, S.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.